DiaSorin GroupCompany PresentationMay 2019

What we do

DiaSorin develops, manufactures and markets tests for the diagnosis of infectious diseases or hormonal disorders in the patient’s health status.

Our offer includes

Our diagnostic tests are aimed at both private and hospital laboratories worldwide, in immunodiagnostic and molecular diagnostic markets.

Me-tootests and

Specialtytests

both with high technological content

We are an Italian multinational Group, listed on the stock exchange in the FTSE MIB. Owned by DiaSorin S.p.A., it consists of 24 Companies, 5 foreign branches, offices on the 5 Continents and 6 manufacturing facilities throughout the world.

We are one of the leading hi-tech players in the in vitro diagnostic market and, in

particular, in the immunodiagnostic and molecular diagnostic

segments.

DiaSorin worldwide

R&D Centers

Manufacturing Sites

USACypress

USAStillwater

South AfricaKyalami

ItalySaluggia

ItalyGerenzano

UKDartford

GermanyDietzenbach 50

yearsof experience,

With over

Our distribution model consists of commercial subsidiaries (Europe, USA, Mexico, Brazil, China, Australia, Israel) and a network of about 200 independent distributors in the rest of the world.

DiaSorin worldwide

2.000employees

We want to reach everyone, wherever they are.

>200researchers

10every year

new

tests 120geographicalfootprint

Our History

Foundation of Sorin, a nuclear energy production research site, In Saluggia(VC, Italy), with the Joint Venture between FIAT and Montecatini. The first in Vitro Diagnostic (IVD) business is developed, focused on the European market

1968 1997 2000 2007 20102011

20132015

2016 2017 2018

Sorin acquires American Incstar Inc., active in the in vitro diagnostics (IVD). All activities related to IVD are spun off in a company named DiaSorin Srl, then sold to American Standard Inc.

With a management buyout operation, DiaSorin returns to Italian ownership

On July 19 DiaSorin is listed on the Stock Exchange

DiaSorin continues its growth by launching the LIAISON® XL. Acquisition of Murex and Abbott's related ELISA product-line, expanding further into Europe, Asia and Africa

DiaSorin is the leading player in the immunodiagnostic sector with the most extensive test menu available on CLIA technology and the highest number of specialty tests. Through strategic agreements with Roche and Beckman Coulter, DiaSorin takes on a truly global dimension

DiaSorin acquires the molecular diagnostic and immunodiagnostic business unit of Focus Diagnostic, today DiaSorin Molecular

With the strategicpartnership with Qiagen, DiaSorin is able to offer an automated solution for the tuberculosis diagnosis

DiaSorin signs a strategic agreement with Meridian Bioscience to sell Helicobater Pylori Stool Antigen test in the United States and the United Kingdom

Expansion of DiaSorin’s installed base

Free Cash FlowNet Financial Position

Financial Results @ March 31, 2019

Cash flow generationand positive financial position

Revenues by geographyQ1’19 vs.Q1'18 at constant exchange rates

+78.3Euro millions

+35.6Euro millions

New LIAISON XLinstalled in Q12019:

+103

Total LIAISON XLworldwide:

4,125

Total installed base LIAISON + LIAISON XL:

7,952

Mexico+16.1%

Brazil-13.8%

Latin America

9.4 €/mln5.5% of sales

-8.5%

USA-4.5%

USA and Canada

48.9 €/mln28.6% of sales

-6.4%

Italy+22.8%

Germany+0.1%

France-0.2%

Europe & Africa

82.0 €/mln48.0% of sales

+6.1%

China+15.1%

Australia+10.9%

Asia Pacific

30.5 €/mln17.9% of sales

+5.1%

Source: Press Release Q1 2019 Results

FY Revenues and EBITDA

Data in€/mln

Ricavi

EBITDA

2012 2013 2014 2015 2016 2017 2018

434

170

435

163

444

160

669

255

217

569

185

499

238

637

Immunodiagnostics

Innovation process in the Immunodiagnostic market: 1970-2019M

ENU

Area of opportunity

AUTOMATION

RIA BENCH-TOP SOLUTIONS

FIRST AUTOMATED SYSTEMS

AUTOMATED SYSTEMS

FULL CONNECTIVITY(Immuno+Clinical Chemistry)

Immunodiagnostics

Technology based on the detection of antibodies to highlight the presence of diseases in a sample of human fluids loaded on proprietary platforms based on CLIA technology (Chemiluminescence) and ELISA technology (Colorimetry)

ELISA SystemsCLIA Systems

FreedomAVAILABLE OUTSIDE THE UNITED STATES AND CANADA

LIAISON family platforms

Same cartridge for each test

100 test samples for each cartridge

Same raw materials

LAS

Magnetic particles DiluentCalibrators

New in 2019

Installed base evolution

LAS

2009 2010 2011 2012 2013 2014 2015 2016 2017

2,959

4,2064,740

5,272

5,8726,336

7,3986,862

3,641

2018

-32

6051,075

1,6652,292

3,5182,863

128

4,001

4,0784,135 4,197 4,207

4,044 3,8803,9993,848

+483

+477 +470+590

+627+571

+128

+682

+437+57

+62-45 -119

+10 -163

+655

7,849

The widest CLIA menu on the market: 121 testsM

ENU

MEN

U

MEN

U

MEN

U

ONCOLOGY

TUMOUR MARKERS CEA

Free PSA

Total PSA

CA 15-3

CA 125 II

CA 19-9

TPA-M

NSE

S100

AFP

Tg Gen II

HCG

ß2-Microglobulin

TK

Calcitonin

ENDOCRINOLOGY

THYROIDTSH (3rd Gen.)

Free T3

Free T4

T3

T4

Anti-Tg

Tg Gen II

Tg Gen Confirmatory II

Anti-TPO

GROWTHhGHIGF-I

ADRENAL FUNCTION ACTHCortisolDHEA-S

ANAEMIAFerritinFolateVitamin B12

DIABETESC-Peptide Insulin

REPRODUCTIVE ENDOCRINOLOGY LH

FSHProlactinProgesterone TestosteroneEstradiolHCGAndrostenedioneSHBG

BONE & MINERAL25-OH Vitamin D TOTALN-TACT PTH II

STOOL DIAGNOSTICSC. difficile GDH

C. difficile Toxin A and BH. Pylori SAEHECRotavirusAdenovirusCalprotectinCampylobacterElastase -1

INFECTIOUS DISEASESZika IgM

PARVOVIRUSParvovirus B19 IgGParvovirus B19IgM

CHRONIC KIDNEY DISEASES1-84 PTHOsteocalcinBAP OSTASE

1,25 dihydroxy Vitamin D

ENDOCRINOLOGY

HYPERTENSIONDirect ReninAldosterone

VIRAL HEPATITIS & RETROVIRUSESAnti-HDV

INFECTIOUS DISEASESEBV EBV IgMVCAIgGEBNA IgGEA IgG

H.PYLORIH. Pylori IgG

TREPONEMATreponema Screen

SEPSISBRAHMS PCT II Gen

TORCHToxo IgGToxo IgMToxo IgG AvidityRubella IgGRubella IgMCMV IgG

CMV IgMCMV IgG AvidityHSV-1/2 IgGHSV-1 IgGHSV-2 IgGHSV-1/2 IgM

BORRELIABorrelia burgdorferi IgGBorrelia burgdorferi IgM

MEASLES & MUMPSMeasles IgGMeasles IgM Mumps IgG Mumps IgM

VZVVZV IgGVZV IgM

VIRAL HEPATITIS & RETROVIRUSESHBsAgHBsAg QuantAnti- HBsAnti- HBs plus Anti- HBc

HBc IgM

HBeAgAnti-HbeAnti-HAVHAV IgM

HCV AbHIV Ab/AgHTLV I/II

CHAGAS

Chagas IgG

CHRONIC KIDNEY DISEASESFGF-23

Ratio (Vitamin D1,25-PTH 1,84)

Sclerostin (for research use only)

BORDETELLABordetella pertussis Toxin IgGBordetella pertussis Toxin IgA

MYCOPLASMAMycoplasma pneumoniae IgGMycoplasma pneumoniae IgM

CHLAMYDIAChlamydia T. IgGChlamydia T. IgA

QuantiFERONQuantiFERON TB Gold Plus

AUTOIMMUNITYANA screenENA screentTG IgACardiolipine IgGCardiolipine IgMDsDNA

Molecular Diagnostics

Technologies in the Molecular Diagnostics marketM

ENU

Area of opportunity

AUTOMATION

Area of opportunity

MOLECULAR DIAGNOSTICS

Molecular Diagnostics

Technology that allows to diagnose a pathology by detecting specific RNA and DNA sequences (nucleid acids) in patients’ biological fluids or abnormal cells.

VersatileSame platform, multiple discs

Our technology: Liaison MDX

TECHNOLOGY Compact. Powerful. Expandable.

Unique technology with no extraction required

Universal Disc (UD)

96 reaction-wells for

high volumes

Direct Amplification Disc(DAD)

8 reaction-wells for

medium-low volumesPCR Based ASRs & Kits